Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
APEX1 rs3136817, MUTYH rs3219493, three SNPs (rs3213356, rs25487 and rs1799782) in XRCC1, and three SNPs (rs1799794, rs861531 and rs861530) in XRCC3 showed significant associations with the risk of bladder cancer.
|
27153553 |
2016 |
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
We identified no association between the XRCC1 Arg399Gln polymorphism and bladder cancer risk.
|
25501209 |
2014 |
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The analysis suggests that the XRCC1 Arg399Gln polymorphism might be a moderate risk factor for bladder cancer, especially in non-Asian population.
|
24176953 |
2014 |
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
We conducted a meta-analysis to ascertain the association of XRCC1 Arg194Trp, Arg280His and Arg399Gln polymorphisms with bladder cancer risk in Asian population.
|
23704969 |
2013 |
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The meta-analysis results suggest that XRCC1 Arg194Trp and Arg399Gln polymorphisms may be associated with elevated bladder cancer risk.
|
23496911 |
2013 |
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
This meta-analysis suggests that the XRCC1 R399Q polymorphism may play a protective role against bladder cancer among smokers.
|
24039945 |
2013 |
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The overall data failed to indicate significant associations between XRCC1 A</span>rg399Gln polymorphism and bladder cancer risk (Gln/Gln versus Arg/Arg: odds ratio (OR) = 0.97; 95% CI = 0.85-1.10; dominant model: OR = 1.02; 95% CI = 0.94-1.09; recessive model: OR = 0.95; 95% CI = 0.84-1.07).
|
23479765 |
2013 |
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Significant increased risk of bladder cancer was observed for Arg194Trp polymorphism (allele comparison OR = 1.20, 95 % CI: 1.06-1.36, P heterogeneity = 0.11; dominant model OR = 1.20, 95 % CI: 1.02-1.41, P heterogeneity = 0.37) and Arg280His polymorphism (heterozygote comparison OR = 1.87, 95 % CI: 1.21-2.90, P heterogeneity = 0.01; dominant model OR = 1.75, 95 % CI: 1.05-2.90, P heterogeneity = 0.01); however, Arg399Gln was not associated with susceptibility to bladder cancer.
|
23636799 |
2013 |
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
We examined the associations between bladder cancer and 7 polymorphisms from 5 genes involved in the maintenance of genetic stability (MMR: MLH1-93G>A; BER: XRCC1--77T>C and Arg399Gln; NER:XPC Lys939Gln and PAT +/-; DSBR:ATM G5557A and XRCC7 G6721T) in 302 incident bladder cancer cases and 311 hospital controls.
|
22927776 |
2012 |
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
No association was found between the polymorphisms in XRCC1 (Arg(194)Trp, Arg(280)His, Arg(399)Gln) and bladder cancer susceptibility.
|
18336890 |
2008 |
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
It indicated that XRCC1 R399Q and R194W might not be risk factors to bladder cancer, but the 399QQ genotype decreased susceptibility of bladder cancer under recessive model and homozygote contrast among ever-smokers.
|
18765423 |
2008 |
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our data are consistent with a potential role of the XRCC1 Arg399Gln polymorphism in bladder cancer susceptibility and further suggest that there may be DNA lesions important in bladder carcinogenesis, repaired by the base excision repair mechanism, that are not directly associated with tobacco smoking.
|
15298955 |
2004 |